- ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
- ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
- ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
- ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
- ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
- ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
- ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
- ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
- ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
More ▼
Key statistics
On Friday, ARS Pharmaceuticals Inc (SPRY:NMQ) closed at 9.10, -19.25% below its 52-week high of 11.27, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.04 |
---|---|
High | 9.19 |
Low | 8.86 |
Bid | 9.10 |
Offer | 9.50 |
Previous close | 9.09 |
Average volume | 1.01m |
---|---|
Shares outstanding | 96.90m |
Free float | 74.16m |
P/E (TTM) | -- |
Market cap | 881.75m USD |
EPS (TTM) | -0.5198 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼